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Abstract: Inflammatory bowel disease (IBD) is a chronic relapsing–remitting systemic disease of the
gastrointestinal tract. It is well established that the gut microbiome has a profound impact on IBD
pathogenesis. Our aim was to systematically review the literature on the IBD gut microbiome and its
usefulness to provide microbiome-based biomarkers. A systematic search of the online bibliographic
database PubMed from inception to August 2020 with screening in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted.
One-hundred and forty-four papers were eligible for inclusion. There was a wide heterogeneity in
microbiome analysis methods or experimental design. The IBD intestinal microbiome was generally
characterized by reduced species richness and diversity, and lower temporal stability, while changes
in the gut microbiome seemed to play a pivotal role in determining the onset of IBD. Multiple studies
have identified certain microbial taxa that are enriched or depleted in IBD, including bacteria, fungi,
viruses, and archaea. The two main features in this sense are the decrease in beneficial bacteria and
the increase in pathogenic bacteria. Significant differences were also present between remission and
relapse IBD status. Shifts in gut microbial community composition and abundance have proven to be
valuable as diagnostic biomarkers. The gut microbiome plays a major role in IBD, yet studies need
to go from casualty to causality. Longitudinal designs including newly diagnosed treatment-naïve
patients are needed to provide insights into the role of microbes in the onset of intestinal inflammation.
A better understanding of the human gut microbiome could provide innovative targets for diagnosis,
prognosis, treatment and even cure of this relevant disease.
Keywords: gut microbiome; inflammatory bowel disease; Crohn’s disease; ulcerative colitis; biomarkers
1. Introduction
The gastrointestinal microbiota comprises a collection of microbial communities,
including viruses, bacteria, archaea and fungi, inhabiting the gastrointestinal tract [1]. The
constitution and diversity of the microbiota in different sections of the gastrointestinal tract
are highly variable and its concentration increases steadily along it, with small numbers
in the stomach and very high concentrations in the colon [2,3]. This community has been
linked to many diseases, including inflammatory bowel disease (IBD) [4].
IBD encompasses a group of chronic inflammatory bowel pathologies of idiopathic
origin that affect millions of people throughout the world; the two most important patholo-
gies covered by this term are Crohn’s disease (CD) and ulcerative colitis (UC) [5]. IBD is
not curable and shows a chronic evolution, with alternating periods of exacerbation and
remission. This situation entails a high burden on health care systems, which try to provide
treatment and to ensure quality of life for these complex patients who often require lifelong
medical attention.
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The microbiota of the gastrointestinal tract is frequently proposed as one of the
key players in the etiopathogenesis of IBD. Studies in animal models and humans have
shown that there is a persistent imbalance of the intestinal microbiome (which refers to
the gut microbiota and their collective genetic material) related to IBD, with a substantial
body of literature providing evidence for the relation of the human gut microbiome and
IBD [4,6–10]. Despite all this evidence, it has been difficult to determine whether these
changes in the microbiome are the cause of IBD or rather the result of inflammation after
IBD onset. The consequence of this relationship between the human gut and microbes
is that pharmacological therapies, diet and other interventions targeted to the host will
also significantly impact the gut microbiota. Most of the existing studies attempting to
determine whether dysbiosis is causative or a consequence of inflammation had certain
limitations, such as disparities in methodologic approaches, including different techniques
used to analyze the gut microbiome, different sampling sites (stool/mucosa) or site of
inflammation, lack of prospective data, small cohort sizes, restricted focus on bacteria,
different disease activities and influence of treatment interventions.
We conducted a systematic review to comprehensively collate the body of evidence
surrounding the relationship between the gut microbiome and IBD. Our objective was to




An electronic search was conducted using the MEDLINE database via PubMed to
identify published articles on the gut microbiome and IBD, from inception to August 2020.
The search strings used were:
[(“ulcerative colitis” [MeSH Terms]) OR (“colitis” [All Fields] AND “ulcerative” [All
Fields]) OR (“ulcerative colitis” [All Fields]) OR (“crohn disease” [MeSH Terms]) OR (“crohn”
[All Fields] AND “disease” [All Fields]) OR (“crohn disease” [All Fields]) OR (“crohn’s disease”
[All Fields]) OR (“inflammatory bowel diseases” [MeSH Terms]) OR (“inflammatory bowel
diseases” [All Fields])] AND (“microbiome” [All Fields] OR “microbiota” [All Fields]).
Moreover, the reference lists of the included studies were revised to identify further
relevant studies.
The work was conducted in accordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses statement in Appendix A [11].
2.2. Eligibility Criteria
The inclusion criteria were intestinal microbiome studies comparing IBD patients
with controls; performed on fecal, intestinal lavage or intestinal tissue samples; focused on
human adults; written in English.
Studies were excluded if they reported data on IBD complications or postsurgery
(pouchitis, fistulae, among others); studied other conditions in addition to IBD (irritable
bowel syndrome, Clostridium difficile infection, primary sclerosing cholangitis, among
others); were abstracts from conference proceedings, letters to editor, reviews or reported
only one patient.
3. Results
A total of 5267 records were identified from the PUBMED database. Of 190 papers
remaining after screening, 23 did not include controls, 22 included other pathologies and 2
were in silico studies. A total of 143 papers were ultimately included.
3.1. Gut Microbiome Studies in IBD: Methodologic Aspects
The main methodologic characteristics of the studies included in this review are
summarized in Table 1 (IBD gut microbiome studies using non-next-generation sequencing
[NGS] approaches) and Table 2 (IBD gut microbiome studies using NGS approaches).
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Table 1. Gut microbiome studies in inflammatory bowel disease using non-next-generation sequencing approaches.
Reference Year Treatment
No. of Participants
Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Macfarlane
et al. [12] 2004 Not naïve NA 9 NA 10 Active Biopsy NA
Cross-
sectional Culture, FISH Bacteria
UC
 Only differences in
bifidobacteria were statistically
significant.
 Peptostreptococci were only
present in UC patients.
Lepage et al.










 Dominant species differ between
the mucosa-associated and fecal
microbiota.
 The microbiota is relatively
stable along the distal digestive
tract.
Manichanh






 Reduced Firmicutes diversity.
Bibiloni et al.










 Bacteria associated with
inflamed and non-inflamed
tissues did not differ.
 UC had more bacteria associated
with biopsies than CD.
 Bacteroidetes were more
prevalent in CD than in UC.
Sokol et al.






 Reduced bacterial diversity.
Gophna et al.










 No significant difference
between inflamed and
non-inflamed tissues.
 In CD, increased Proteobacteria
and Bacteroidetes and reduced
Clostridia.
 No difference between UC and
HC.
Scanlan et al.
[18] 2006 Not naïve 16 NA NA 6 Active/Inactive Stool NA Longitudinal DGGE (16S rDNA) Bacteria
CD
 Lower temporal bacterial
stability but higher stability for
remission patients.
 Lactic acid bacteria spp. varied
significantly between the CD
groups.
 Decrease in Clostridium and
Bacteroides spp.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Zhang et al.








 Lactobacilli and the Clostridium
leptum subgroup were
significantly different between
the inflamed and non-inflamed
tissues. They were also affected
by UC location.
Sepehri et al.




sectional ARISA, T-RFLP Bacteria
CD and UC
 Differences between inflamed
and non-inflamed tissues were
found.
 The non-inflamed tissues form
an intermediate population
between HC and inflamed tissue
for both CD and UC.
Andoh et al.
[21] 2007 Not naïve NA 44 NA 46 Active/Inactive Stool NA
Cross-
sectional T-RFLP (16S rDNA) Bacteria
UC
 Bacterial communities are
different between HC and active
UC patients and between active
and inactive patients.
 Eubacterium, and Fusobacterium
were predominantly detected in
the active patients.
 Lactobacillus were more
predominant in the inactive
patients.
Frank et al.












 Significant differences between
the microbiotas of CD and UC
and those of non-IBD controls.
 Depletion of members of the
phyla Firmicutes and
Bacteroidetes.
Ott et al. [23] 2008 Not naïve NA 13 NA 5 Active/Inactive Biopsy NA Longitudinal PCR, cloning andsequencing Bacteria
UC
 Temporal instability and
bacterial richness decreased in
relapsing patients compared to
remission.







 Increased fungal richness and
diversity in CD.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Martinez et al.




 Temporal instability and
reduced diversity in remission
patients.
Dicksved








 Decreased bacterial diversity.
 Decreased Bacteroides uniformis
and increased B. ovatus and B.
vulgatus.
 Ileal CD bacterial communities
were significantly different from
HC and colonic CD.
Kuehbacher









 TM7 (subgroup of
Gram-positive uncultivable
bacteria) were more diverse in
CD than in UC and non-IBD
controls.
Andoh et al.
[28] 2008 Not naïve 34 NA NA 30 Active/Inactive Stool NA
Cross-
sectional T-RFLP (16S rDNA) Bacteria
CD
 Decrease in Clostridium cluster
IV, Clostridium cluster XI and
subcluster XIVa.
 Increase in Bacteroides and
Enterobacteriales.
Nishikawa
et al. [29] 2009 Not naïve 9 NA NA 11 Active/Inactive Biopsy
Inflamed/non-
inflamed Longitudinal T-RFLP (16S rDNA) Bacteria
UC
 Decreased diversity due to loss
of commensals.
 Decreased diversity in inactive
patients compared to active
patients.
Willing et al.










 Ileal CD had a lower abundance
of Faecalibacterium prausnitzii
and an increased abundance of
Escherichia coli compared to
healthy co- twins and colonic
CD.
 Dysbiosis was significantly
correlated to the disease
phenotype.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Andoh et al.
[31] 2009 Not naïve NA 2 NA 3Ur Inactive Stool NA
Cross-
sectional T-RFLP (16S rDNA) Bacteria
UC
 Increase in Clostridium cluster IX
and decreases in Clostridium
cluster XIVa.
Gillevet et al.












 Mucosal microbiome is distinct
from the luminal microbiome in
HC.
 Mucosal microbiome appears to
be dysbiotic in IBD.
Rehman et al.








 Increase in Escherichia sp.
Kang et al.






 Decreased Eubacterium rec- tale,
B. fragilis group, B. vulgatus,
Ruminococcus albus, R. callidus,
R. bromii, and F. prausnitzii.
 Increased Enterococcus sp.,
Clostridium difficile, E. coli,
Shigella flexneri, and Listeria sp.
Rowan et al.






 Increase in Desulfovibrio, more
marked in acute phase.
Andoh et al.






 Decrease in the Clostridium
family in active UC and
inactive/active CD.
 Increase in Bacteroides.
 Inactive UC tended to be closer
to that of HC.
Mondot et al.
[37] 2011 Not naïve 16 NA NA 16 Active Stool NA
Cross-
sectional
qPCR, RT qPCR (16S
rDNA) Bacteria
CD
 Decrease in F. prausnitzii
Ruminococcus bromii,
Oscillibacter valericigenes,
Bifidobacterium bifidum, and E.
rectale.
 Increase in E. coli and
Enterococcus faecium.
 More marked increase in E. coli
in ileal CD.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Joossens et al.
[38] 2011 Not naïve 68 NA NA
84 Ur +






 Decrease in Dialister invisus
species of Clostridium cluster
XIVa, F. prausnitzii and
Bifidobacterium adolescentis.
 Increase in R. gnavus.
Lepage et al.








 Decreased bacterial diversity.
 Increase in Actinobacteria and
Proteobacteria.
 Healthy siblings from discordant
twins had more bacteria from
the Lachnospiraceae and
Ruminococcaceae families than
twins who were both healthy.
Benjamin
et al. [40] 2012 Not naïve 103 NA NA 66 Active Stool NA
Cross-
sectional FISH (16S rDNA) Bacteria
CD
 Increase in Bacteroides-Prevotella
in smokers (38.4%) compared
with nonsmokers (28.1%).
 Increase in bifidobacterial and
Bacteroides-Prevotella.
 Decrease in F. prausnitzii.
Hotte et al.




sectional T-RFLP (16S rDNA) Bacteria
CD and UC
 Increase in Proteobacteria
compared with HC and UC.
Pistone et al.



















 Decrease in Clostridia in active
disease and remission and in
Bifidobacterium in active phase
but increased during remission.
 Increase in Bacteroides genus in
active.
 Decreased bacterial diversity.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C










 Decreased bacterial diversity.
 Increase in γ-Proteobacteria
(especially E. coli and S. flexneri).
 Decrease in reduced
Bacteroidetes and Firmicutes.
 In ulcerated mucosa, E. coli was
increased and F. prausnitzii,
Lactobacillus coleohominis,











 Decreased bacterial diversity.
 Decrease in Bacteroides and
Clostridium subcluster XIVab.
 Increase in Enterococcus.
Vigsnæs et al.









 Different microbiota in active
UC compared to HC but in
inactive UC compared to HC.
 Decrease in Lactobacillus spp.
and Akkermansia muciniphila in
active disease.
de Souza et al.






sectional Culture E. coli
CD and UC
 Only the mucosa-associated
population of E. coli was
increased, not in stool. The
increase was prominent in the
ileal CD and rectum and
sigmoid of both UC and CD.
Duboc et al.
[48] 2013 Not naïve 12 30 NA 26 Active/Inactive Stool NA
Cross-
sectional PCR (rDNA), culture Bacteria
CD and UC
 Decrease in the ratio between F.
prausntizii and E. coli






 Decrease in the numbers of
Bacteroides–Porphyromonas–
Prevotella, Bifidobacterium and
B. fragilis in active phase.
 Decrease in Helicobacter and
Clostridium phylogenetic
clusters XI and XIVa in active
and inactive phases.
 Increase in E. coli in active
phases.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Kabeerdoss









 Decrease in C. leptum group
bacteria and F. prausnitzii.
 Decreased bacterial diversity.
Varela et al.
[51] 2013 Not naïve NA 116 NA
29 Ur +







 Decrease in F. prausnitzii in
patients and relatives.
 Recovery of the F. prausnitzii
population after relapse was
associated with remission.
Midtvedt






 Decrease in Bacteroides in both
stool and biopsies.
Fujimoto et al.










 Decrease in Clostridia, including
the genus Faecalibacterium.
 Decreased bacterial diversity.
Fite et al. [54] 2013 Not naïve NA 33 NA 18 Active Biopsy Inflamed Longitudinal qPCR Bacteria
UC
 High clinical activity indices
were associated with
enterobacteria, desulfovibrios,
type E Clostridium perfringens,
and Enterococcus faecalis.
 Low clinical activity indices
were associated with Clostridium
butyricum, R. albus, Lactobacillus,




2013 Not naïve NA 15 NA 15 Inactive Stool NA Longitudinal Microarray Bacteria
UC
 Decrease in members of the
Clostridium cluster IV R. bromii et
rel. E. rectale et rel., Roseburia sp.,
and Akkermansia sp.
 Increase in Fusobacterium sp.,
Peptostreptococcus sp.,
Helicobacter sp., Campylobacter sp.
and C. difficile.
Kumari et al.








 Decrease in C. coccoides and C.
leptum clusters.
 F. prausnitzii and Roseburia
intestinalis were differentially
present in patients with different
disease activity.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Hedin et al.
[57] 2014 Not naïve 22 NA NA
25 +
21Ur Inactive Stool NA
Cross-
sectional qPCR (16S rDNA) Bacteria
CD
 Siblings shared dysbiosis pattern
with patients (lower
concentrations of F. prausnitzii,
Clostridia cluster IV and
Roseburia spp.).
Lennon et al.
[58] 2014 Not naïve NA 19 NA 34 Active Biopsy NA
Cross-




 No significant differences in
Desulfovibrio sp. were found
between cohorts or at each
sampling region between the
cohorts.
Machiels et al.
[59] 2014 Not naïve NA 127 NA 447 Active/Inactive Stool NA
Cross-
sectional





 Decrease in Roseburia hominis
and F. prausnitzii.
 R. hominis and F. prausnitzii
showed an inverse correlation
with disease activity.
Wang et al.






sectional qPCR (16S rDNA) Bacteria
CD and UC
 Bifidobacterium was increased in
biopsies of active UC patients,
and higher in the biopsies than
in the fecal samples in active CD
patients.
 Lactobacillus group was s
increased in biopsies of active
CD patients.
 F. prausnitzii was decreased in
both the fecal and biopsy
specimens of the active patients.
Blais Lecours






 Increase in Methanosphaera
stadtmanae.
Fukuda et al.








 Development of a Discriminant
Score based on selected OTUs.
 Five differential clusters were
obtained indicating a strong
association between the gut
microbiota and UC *.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C








 Increase in fungal richness and
diversity in the inflamed mucosa
compared with the
non-inflamed mucosa.




 In stool, increase in fungal
diversity and prevalence in
Candida albicans, Aspergillus
clavatus, and C. neoformans.
Andoh et al.




 Decision tree based on selected
OTUs, obtaining 9 groups.
 Microbiota profiles may differ
according to disease activity.
Wisittipanit







 Development of a computational
pipeline to characterise the gut
microbial communities.
 Model could classify IBD from
HC at specific locations and
based on disease state *.
Kabeerdoss
et al. [66] 2015
Naïve and








 Increase in Bacteroides and
Lactobacillus in UC patients
compared with controls or CD.
 Increase in E. coli in UC
compared with controls.
 Decrease in C. coccoides group
and C. leptum group in CD
compared with controls.
 Decrease in Firmicutes to
Bacteroidetes ratio in UC and
CD.
 No differences between
inflamed and non-inflamed
tissues were found, nor between
treated and untreated patients.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Takeshita




 Decrease bacterial diversity in
active phase.
 Fusicatenibacter saccharivorans
was decreased in active patients
and increased in quiescent.
Zhang et al.




 Increase in E. coli and
Enterococcus sp. in active phase











 Increased total bacterial DNA
concentration levels in active
phase compared to the inactive.
 Increase in Bacteroides spp. in
active and inactive phases.
 Decrease in C. leptum group (IV),
and F. prausnitzi in active and
inactive phases.
Zamani et al.
[70] 2017 Not naïve NA 35 NA 60 Active Biopsy Inflamed
Cross-
sectional Culture, qPCR Bacteria
UC
 No association between B.
fragilis and UC.
 Enterotoxigenic B. fragilis was
more prevalent in UC patients
with diarrhea.
Ghavami











 Decrease in Methanobrevibacter
smithii.
 More marked increase in Mbb.
smithii in remission than in
active phase.
Le Baut et al.











 Increase in Yersinia species.
Al-Bayati






 Decrease in F. prausnitzii,
Prevotella, and
Peptostreptococcus productus.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Heidarian




 Decrease in Bacteroides, F.
prausnitzii, Prevotella spp., and
Methanobrevibacterium.
 Decrease in Bacteroides spp., F.
prausnitzii, and Prevotella spp.
in UC patients with disease
activity score greater than 4.
 Increase in Streptococcus and
Haemophilus in the patients












 Decrease in Firmicutes and
Eubacterium hallii.
 Increase in Bifidobacterium spp.,
E. hallii, Actinobacteria and
Firmicutes in ulcerative proctitis,
compared to extensive colitis.
 No association with disease
location in CD.
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; IBDU, inflammatory bowel disease unclassified; HC, healthy control; C, control; NA, not applicable; FISH,
fluorescence in situ hybridization; TTGE, temporal temperature gradient gel electrophoresis; DGGE, denaturing gradient gel electrophoresis; qPCR, quantitative real-time polymerase chain reaction; ARISA,
automated ribosomal intergenic spacer analysis; T-RFLP, terminal restriction fragment length polymorphism; Ur, unaffected relatives; LH-PCR, length heterogeneity polymerase chain reaction; OTUs, operational
taxonomic unit. * No microorganisms specified.
Table 2. Gut microbiome studies in inflammatory bowel disease using next-generation sequencing approaches.
Reference Year Treatment
No. of Participants
Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Willing et al.










 Ileal CD differed from colonic
CD.
 In ileal CD, decrease in
Faecalibacterium and Roseburia,
and increase in Enterobacteriaceae
and Ruminococcus gnavus.
Rausch et al.


















Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Walker et al.








 Decrease in bacterial diversity.
 Decrease in Firmicutes and
increase in Bacteroidetes, and in
CD only, Enterobacteriaceae.
 Differences between inflamed
and non-inflamed tissues were
found.
Erickson et al.




region and WGS Bacteria
CD
 Decrease in bacterial diversity.
 Decrease in Firmicutes in ileal
CD.
Morgan et al.






region and WGS Bacteria
CD and UC










 Microbiota of Norwegian CD
patients was found to be similar
to that of CD patients in other
countries.









 Decrease in C. coccoides-E.
rectales group in ileal CD
compared to control non-IBD.
 Decrease in F. prausnitzii in CD.
Tong et al.







16S rDNA V4 region
sequencing Bacteria
CD and UC
 Decrease in Firmicutes and
increase in Proteobacteria and
Actinobacteria.
 Decrease in microbial diversity
Thorkildsen






 Increase in Escherichia/Shigella
in CD.
 Decrease in Faecalibacterium in
CD compared to both UC and
controls.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Prideaux et al.












 Decrease in microbial diversity
and in Faecalibacterium,
Coprococcus, Dorea, Roseburia,
and 2 unclassified gener (from
Lachnospiraceae and Clostridiales)
in CD.
 In UC, diversity was reduced in
Chinese subjects.
 Actinobacteria was significantly
different between the UC
groups.
 Decrease in Coprococcus and
Dorea genera in UC.
Chiodini et al.








 Separation of the submucosal
and mucosal microbiome and




et al. [87] 2013
Naïve and
not naïve 11 NA NA 8 NA Stool NA
Cross-
sectional






 Decreased bacterial and viral
diversity.
 Synechococcus phage S CBS1 and
Retroviridae family viruses were
more represented in CD.
 Increase in Proteobacteria and




et al. [88] 2014 Not naïve 13 14 NA 27 NA Biopsy Inflamed
Cross-
sectional
16S rDNA V4 region
sequencing Bacteria
CD and UC
 Decreased bacterial diversity.
 No phylum-level significant
differences in Firmicutes or
Proteobacteria
 Bacteroidetes were only
increased in CD.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Chen et al.










 Decrease in Roseburia,
Coprococcus, and
Ruminococcus.
 Increase in Escherichia-Shigella
and Enterococcus.
 Fecal- and mucosa-associated
microbiota were similar between
CD and UC and differed from
HC.
Wang et al.

























16S rDNA V4 region
sequencing Bacteria
UC
 Spatial variation between the
luminal and mucosal
communities in both cohorts.
 Decrease in Bacteroidaceae and
Akkermanseaceae.






an uncultured member of the
Prevotellaceae family.
Chiodini et al.
[92] 2015 Not naïve 20 NA NA 15 NA Biopsy Inflamed
Cross-
sectional
16S rDNA V4 region
sequencing Bacteria
CD
 Distinct sub- mucosal
microbiome compared to
mucosa and/or fecal material.
 Desulfovibrionales were present
within the submucosal tissues.
 Increase in Firmicutes in the
subjacent submucosa as
compared to the parallel
mucosal tissue.








Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Pérez-Brocal
et al. [93] 2015
Naïve and














 Decrease bacterial diversity in
all CD groups.
 Increased richness and diversity
were observed in feces
compared with biopsies.












 Decrease in Clostridia and
increase in Bacteroidetes and
Proteobacteria.
 No detection of F. prausnitzii.
Norman et al.






 Increase in Caudovirales
bacteriophages.
 It did not appear that expansion
and diversification of the enteric
virome was secondary to
changes in the microbiota.






 Decrease in bacterial diversity.
 Increase in Proteobacteria was
increased in both fecal and
mucosal tissues, and
Fusobacteria only in tissue
samples.
 Increase in Gammaproteobacteria
and Fusobacteria in both fecal
and mucosal tissue samples in
active phase.
Chiodini et al.










Prevotellaceae in the submucosa
at the advancing disease margin
when compared to the
superjacent mucosa
(translocation).




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Rehman et al.






 Proteobacteria decrease in UC
compared with CD and HC.
 Different microbial pattern
based on geographical origin.
Takahashi
et al. [99] 2016 Not naïve 68 NA NA 10 Active/Inactive Stool NA
Cross-
sectional





 Decrease in Bacteroides,
Eubacterium, Faecalibacterium
and Ruminococcus.
 Increase in Actinomyces and
Bifidobacterium.
Forbes et al.





16S rDNA V6 region
sequencing Bacteria
CD and UC
 No difference between inflamed
and non-inflamed tissues were
found. There were only
differences between the
inflamed and non-inflamed
mucosa between CD and UC.
 Increase in Bacteroidetes and
Fusobacteria in inflamed CD
mucosa than in inflamed UC
mucosa.
 Proteobacteria and Firmicutes
were more frequently in the
inflamed UC mucosa.
Liguori et al.












 Decrease in bacterial diversity.
 Increase in Proteobacteria and
Fusobacteria.
 Increase in fungal load in active
phase. Cystofilobasidiaceae family
and Candida glabrata species
were overrepresented.
Mar et al.









 Decrease in bacterial diversity.
 Decrease in Bacteroides and
Prevotella species and Alternaria
alternata, Aspergillus flavus,
Aspergillus cibarius, and Candida
sojae.
 Increase in Streptococcus,
Bifidobacterium, and Enterococcus
and Candida albicans and
Debaryomyces.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Hoarau et al.
[103] 2016 Not naïve 20 NA NA
21 +
28Ur Active/Inactive Stool NA
Cross-
sectional





 Increase in Serratia marcescens
and E. coli, and Candida
tropicalis.
Hedin et al.






 Decrease in bacterial diversity.
 Decrease in F. prausnitzii.
Naftali et al.






 Difference between ileal CD
compared with colonic CD. This
separation was unaffected by the
biopsy’s location, its
inflammatory state or disease
state.
 Faecalibacterium was strongly
reduced in ileal CD compared
with colonic CD, whereas
Enterobacteriaceae were more
abundant in the former.
Pedamallu






 Decrease in Bacteroidetes and
Clostridia.
 Enrichment of enterotoxigenic
Staphylococcus aureus and an
environmental Mycobacterium
species within deeper layers of
the ileum.
Sokol et al.











ratio and C. albicans.
 Decrease in Saccharomyces
cerevisiae.
 Correlations between bacterial
and fungal components.
Santoru et al.








 Increase in Firmicutes,
Proteobacteria, Verrucomicrobia,
and Fusobacteria.
 Decrease in Bacteroidetes and
Cyanobacteria.
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Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Pascal et al.
[109] 2017 Not naïve 34 33 NA
40 +
71Ur Active/Inactive Stool NA Longitudinal
16S rDNA V4 region
sequencing Bacteria
CD and UC
 Dysbiosis was greater in CD
than UC, as shown by a more
reduced diversity, a less stable
microbial community.
Chen et al.






 Decrease in Firmicutes, (Blautia,
Clostridium, Coprococcus and
Roseburia).
 Decreased bacterial diversity.
Hall et al.
[111] 2017 Not naïve 9 10 1 12 Active/Inactive Stool NA Longitudinal WGS Bacteria
CD and UC
 Increase in facultative anaerobes.

























 Decrease in bacterial diversity.
 Decrease in Ruminococcaceae,
Rikenellaceae, and
Christensenellaceae.
 Increase in Enterobacteriaceae.
Ji et al. [114] 2018 Not naïve 51 66 NA 66 Active/Inactive Stool NA Cross-sectional
16S rDNA V4 region
sequencing Bacteria
CD and UC
 Results were different between
HC and IBD patients and
between active and inactive
patients.
Imhann et al.
[115] 2018 Not naïve 188 107 18 582 Active/Inactive Stool NA
Cross-
sectional
16S rDNA V4 region
sequencing Bacteria
CD and UC
 Colonic CD was different from
that of patients with ileal CD,
with a decrease in alpha
diversity associated with ileal
CD.
 Decrease in the genus Roseburia
was associated with higher IBD
risk score.
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 No significant difference among
anatomical sites within
individuals.
 Increase in Proteobacteria and
decrease in Firmicutes and
Bacteroidetes in CD.
 Greater abundance of Escherichia,
Ruminococcus (R. gnavus),
Clostridium, Cetobacterium,
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not naïve 30 21 NA 11 Active/Inactive Stool NA Longitudinal WGS Bacteria
CD and UC
 Decrease in bacterial diversity.
 Decrease in Firmicutes and
increase in Enterobacteriaceae.
 Longitudinal profiles showed
taxonomic shifts in community
composition over time that
coincided with changes in
disease severity.
Chiodini et al.








 Increase in bacterial richness.




penetrated the mucosal surfaces.
Hirano et al.





16S rDNA V4 region
sequencing Bacteria
UC
 Decrease in bacterial diversity.
 Increase in Cloacibacterium and
the Tissierellaceae and decrease in
Neisseria in inflamed site when
compared to the non-inflamed
site.
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Ma et al.
[121] 2018 Not naïve 15 14 NA 13 Active/Inactive Stool NA
Cross-
sectional
16S rDNA V4 region
sequencing Bacteria
CD and UC
 Increase in Proteobacteria.
 Decrease in Bacteroidetes in the
active CD compared to inactive
CD.
 Bacteroidetes showed a negative
correlation with the CD activity
index scores.
Walujkar et al.
[122] 2018 Not naïve NA 12 NA 7 Active Biopsy Inflamed Longitudinal
16S rDNA V4 region
sequencing Bacteria
UC
 Increase in bacterial count in
active UC.











16S rDNA V4 region
sequencing Bacteria
UC
 No difference in bacterial
diversity.
 Proteobacteria were higher in









 Decreased bacterial diversity.
 Decrease in Clostridium cluster
IV, Roseburia, and F. prausnitzii
only in CD.
Libertucci










 Increase in Escherichia and a
decrease in Firmicutes in
inflamed tissue.
 Bacterial diversity did not
correlate with inflammation.
Moustafa




 Decreased bacterial diversity.
 Increase in Proteobacteria and
decrease in Bacteroidetes and
Firmicutes.
O’Brien et al.








 No bacterial imbalance or
reduced diversity in CD
aphthous ulcers and adjacent
mucosa, relative to control
biopsies.
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 Decrease in bacterial diversity
and richness.
 Decrease in F. prausnitzii.
Zuo et al.





VLP and 16S rDNA
sequencing Viruses
UC
 Increase in Caudovirales
bacteriophages, but decrease in
mucosa Caudovirales diversity,
richness and evenness.
 Virome correlated with intestinal
inflammation.
 Increase in Escherichia phage and
Enterobacteria phage.
Altomare










 Fecal microbiota was more
similar to controls than mucosal
microbiota.
 In the colon district some
specific bacterial biomarkers
were identified:
Enterobacteriaceae for IBD stools,
Bacteroides for IBD biopsies.
Franzosa et al.




 Decreased bacterial diversity.
 Decrease in Firmicutes and
increase in Proteobacteria.
 Disease localization did not have
a significant effect among CD
subjects.
Lloyd-Price









 Increase in facultative anaerobes
at the expense of obligate
anaerobes.
 Periods of disease activity were
marked by increases in temporal
taxonomic variability.
Imai et al.









 Decrease in bacterial diversity in
CD compared to HC and UC.
 No difference in fungal diversity.
 Increase in Candida in CD
compared to HC and UC.
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 Proteobacteria was positively
associated with ileal CD and









 Decrease in richness, diversity
and Firmicutes in active and in
aggressive CD.
 Increase in Proteobacteria in CD.
Clooney et al.








 No changes in viral richness.
 Increase in Caudovirales.
 Changes in virome reflected
alterations bacteriome.
Braun et al.
[137] 2019 Not naïve 45 NA NA 22 Inactive Stool NA Longitudinal
16S rDNA V4 region
sequencing Bacteria
CD
 Decrease in bacterial diversity.
 Inactive patients preceding flare
showed a decrease in
Christensenellaceae and S24.7, and
increase in Gemellaceae compared
with those in remission.
Galazzo et al.
[138] 2019 Not naïve 57 NA NA 15 Active/Inactive Stool NA Longitudinal
16S rDNA V4 region
sequencing Bacteria
CD
 Decrease in bacterial diversity
and richness.
 Microbial community structure
was less stable over time.
Sun et al.






 Decreased bacterial diversity.
 Firmicutes and Bacteroidetes,
were the most abundant active
UC and inactive UC,
respectively.
 Increase in Proteobacteria and
Fusobacteria and decrease in
Firmicutes and Bacteroidetes in
active UC.
Yilmaz et al.






 Decrease in diversity in CD
compared with UC and HC.
 Firmicutes were higher than
Bacteroidetes in UC compared
with CD.
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 Decrease in bacterial diversity.






[142] 2019 Not naïve NA 63 NA 30 Active/Inactive Stool NA
Cross-
sectional






Lachnospiraceae and increase in
Enterococcus and Streptococcus.
Alam et al.






 Decrease in bacterial diversity.
 Increase in Firmicutes
Prevotellaceae and decrease
Bacteroidetes in UC.
 Increase in Prevotellaceae and
decrease in Bacteroidetes in CD.
Ryan et al.








 Difference in inflamed and
non-inflamed colonic segments
in both CD and UC.
 Inflammatory status did not
appear to affect diversity.
Butera et al.








 High IL-13mRNA patients are
younger at diagnosis and show
higher prevalence of extensive
colitis than low IL-13mRNA
patients.
 Increase in Prevotella in patients
with high IL-13mRNA tissue
content and Sutterella and
Acidaminococcus in patients with
low IL-13mRNA tissue content.
Boland et al.
[146] 2020 No naïve 101 99 15 48 Active/Inactive Biopsy NA
Cross-
sectional
16S rDNA V4 region
sequencing Bacteria
CD and UC
 CD mucosal biopsy who
achieved mucosal healing had
lower diversity than biopsies
from patients with UC or HC.
 Diversity was differently related
to mucosal healing in CD and
UC.
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 Decreased bacterial diversity.
 Overrepresentation of Tyzzerella
4.
 No difference in diversity in
inflamed and non-inflamed ileal
mucosa.
Shahir et al.








 Decreased bacterial diversity.
Distinct profile in colon and
ileum.
 Increase in obligate anaerobes in
the ileum, B. fragilis was
dramatically increased.
Park et al.




 Diversity was more decreased in
patients with worse prognosis.
 E. coli might be causally
involved in CD progression.
Clooney et al.




 Decrease in bacterial diversity
but increase in variability.
 Reduced temporal microbiota
stability, particularly in patients
with changes in disease activity.
Park et al.






 Decrease in bacterial diversity.
 Different diversity and
identification of differentially
abundant taxa in affected IBD
relatives.
Lo Sasso et al.
[152] 2020 No naïve 41 43 NA 42 Active Stool NA
Cross-
sectional
16S rDNA V4 region
and WGS Bacteria
CD and UC
 Increase in Proteobacteria,
Actinobacteria, and Fusobacteria
 Decrease in Firmicutes,
Bacteroidetes, and
Verrucomicrobia.




Disease State Specimen Histology Design
Microbiome
Analysis Method Focus Microbiota FindingsCD UC IBD/IBDU HC/C
Borren et al.
[153] 2020 No naïve 108 56 NA NA Inactive Stool NA Longitudinal WGS Bacteria
CD and UC
 Increase in Proteobacteria and
Fusobacteria and, at the species
level, Lachnospiraceae_
bacterium_2_1_58FAA in relapse.
 Potential microbial biomarker to
identify proinflammatory state
in quiescent IBD that
predisposes to clinical relapse.
Rubbens et al.








 Decrease in bacterial diversity.
 Potential of flow cytometry to
perform rapid diagnostics of
microbiome profile.
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; IBDU, inflammatory bowel disease unclassified; HC, healthy control; C, control; NA, not applicable; Ur, unaffected
relatives; WGS, whole-genome shotgun sequencing; qPCR, quantitative real-time polymerase chain reaction; VLP, virus-like particle; ITS, internal transcribed spacer.
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3.1.1. Study Design
Across the included studies, populations ranged from 2 to 531 patients, many of
them with a small sample size that reduced the precision of the estimations. Thus, since
many results are limited by sample size, further studies with larger cohorts are desirable to
confirm these results and to clarify the significance of the microbiome in the pathogenesis
of IBD.
In addition, to date, most published studies in IBD are cross-sectional (121 out of the
143 reviewed studies). However, longitudinal designs are required to capture changes
that precede or coincide with disease and symptom onset, and to mechanistically relate
microbiome shifts with disease pathogenesis. Overall, longitudinal studies in IBD (only
15% of the included studies) indicate that there is decreased stability in the microbiota
composition in UC and CD patients [18,23,25,118,131,132,138,149]. These dynamic changes
emphasize the importance of longitudinal sampling for a better understanding of taxa
stability in individuals.
The IBD microbiome varies not only over time but also with treatment [80,155,156].
Newly diagnosed patients with no treatment provide an ideal scenario to study the poten-
tial etiopathogenesis related to intestinal dysbiosis that occurs in IBD. Mouse and human
studies have proven that the gut microbiome is required for disease onset, as germ-free
mice rarely develop the disease [157,158], antibiotics can prevent disease onset in mice [159]
and ameliorate (but not cure) the disease in humans [160].
However, prior IBD microbiome studies have mostly included subjects with an es-
tablished treatment; of the 143 microbiome studies included herein, only 11 included
treatment-naïve patients [15,66,69,75,81,84,87,93,117,118,123], sometimes only on a small
subset of the cohort, and only one was conducted prospectively.
Results on newly diagnosed treatment-naïve patients showed that gut dysbiosis is
already established at the beginning of the disease. The dysbiotic profile in the gut of
newly diagnosed treatment-naïve IBD patients presents reduced microbial abundance,
less biodiversity in the structure of microbial communities, and differential bacterial abun-
dances compared to the profile of established and treated IBD patients or control groups.
Conversely, one study showed none or minor microbial differences between these patients
and a control group [84].
Current knowledge, despite some controversy, provides valuable insights supporting
the idea that microbial alterations may precede IBD onset. Given the limited number of
studies in this type of patients, no consistent conclusion can be inferred, and further work
is needed to investigate in depth the gut dysbiosis of newly diagnosed treatment-naïve
IBD patients.
3.1.2. Microbiome Analysis Methods
Culture-independent and -dependent methods for microbial community analysis have
both been used to describe microorganisms from different environments, including the
human gut. However, due to the inability to culture the majority of the resident bacteria
from the gastrointestinal tract, culture-independent methods have proven much more
reliable and faster in profiling complex microbial communities.
Culture-independent techniques are based on sequence divergences of the small sub-
unit ribosomal RNA (16S rRNA) or other target gene regions. Some of these techniques are
quantitative real-time PCR (qPCR), denaturing gradient gel electrophoresis (DGGE), termi-
nal restriction fragment length polymorphism (T-RFLP), fluorescence in situ hybridization
(FISH), DNA microarrays, and NGS. All these techniques, except for NGS, are referred
herein as non-NGS techniques.
Currently, there are many differences in study design and methodology among studies,
making translation of basic science results into clinical practice a challenging task. Among
the studies included in this review, very few used culture-dependent techniques (7 out of
143); and over the years, NGS became the most employed technique—79 studies used NGS,
while 64 studies used non-NGS approaches.
Microorganisms 2021, 9, 977 29 of 43
Lately, the most widely used approaches are amplicon gene sequencing, predom-
inantly the 16S rRNA gene (16S rDNA), and whole-genome shotgun sequencing, both
NGS techniques.
Another recent technique much less used in this field is flow cytometry. A recent
study demonstrated that cytometry fingerprints can be used as a diagnostic tool to classify
samples according to CD state [154]. These results highlight the potential of flow cytometry
as a tool to conduct rapid and cheaper diagnostics of microbiome-associated diseases.
3.1.3. Sample Type and Site
Currently, bacterial diversity in the human gut is determined through analysis of the
luminal content (stool) and mucosal biopsies; however, the stool microbiome differs from
the mucosa-associated microbiome [161]. Most of the bacteria are tightly adhered to the
mucus and this mucosa-adhered microbiota may be associated with the pathogenesis of the
disease [9,76]. Changes observed in stool samples likely represent an indirect measure of
what is happening at the mucosal surface, where microorganisms interact more intimately
with the host and induce disease.
The studies reviewed herein used fecal data, biopsy data or both, and most of them
showed differences between fecal and biopsy samples [13,32,47,80,89,93,96,130], although
a few studies found similarities [52,76]. The reported differences in microbial composition
related to whether the sample origin was fecal or mucosal indicate that each biological sam-
ple represents a different environment thus emphasizing the importance of experimental
design. Biopsies are primarily recommended for the dissection of the complex pathogene-
sis of IBD, whereas feces could effectively detect key biomarkers, enabling non-invasive
continuous disease monitoring.
In biopsy samples, sampling site can also be a confounding factor. Many studies
have compared the microbiome of inflamed and non-inflamed tissue from the same IBD
patient. Regarding the effect of gut inflammation on the microbiota, there are some dis-
crepancies among studies. Some researchers did not find significant differences in the
mucosa-associated bacteria between apparently normal and inflamed mucosa in IBD
patients [15,66,100,127,128,147]. Conversely, other studies found gut microbiome differ-
ences between inflamed and non-inflamed regions in mucosal biopsies [19,44,72,78,120,
125,134,144]. This difference was also observed in fungal communities of inflamed mucosa,
which are distinguishable from those of the non-inflamed area [63].
In spite of the controversial results, there is evidence supporting that inflamed and
non-inflamed tissue samples in both CD and UC may present some differential microbiota
composition suggesting that a comparison of mucosal samples obtained from identical
sites in IBD patients and non-IBD controls is needed to avoid the confounding effect of
inflammation in the assessment of the microbial profile.
3.1.4. Structural and Functional Analysis
IBD microbiome studies have typically focused on characterizing the composition of a
community and less attention has been paid to functional profiles of the microbes within a
community. Functional information can be inferred from the taxa through bioinformatic
approaches or directly assessed via whole-genome shotgun sequencing.
Function is more informative than taxonomy [162] as it provides information on
possible mechanisms acting on microbes and on microbe–host interactions, which are
important for understanding microbial communities, specially microbiome-related diseases.
The loss of a particular function could be more biologically meaningful than the loss of a
single or a group of species.
The vast majority of the studies published on the IBD microbiome to date have focused
on taxonomy and the reported associations in the IBD gut microbiome are largely limited
to identifying high-level taxonomic classification (ranging from phyla to genera) given, for
example, the limitations of amplicon gene sequencing for reliable species identification.
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Some IBD gut microbiome studies have assessed the change in microbial function
compared to healthy subjects. Outcomes of such studies showed a quite distinct change in
microbial functions, such as fecal tryptic activity, oxidative response or lipid and glycan
metabolism pathways [52,80,83,88,132]. Based on these results, it is necessary to redirect
the study of dysbiosis from a purely compositional definition to a definition that includes
functional changes of the microbiota.
3.2. Dysbiosis in IBD
The microbiome is different among healthy individuals around the globe [163], and the
great differences found between the microbiomes of apparently healthy people complicate
the definition of a healthy microbiome. Despite this divergence, the vast and diverse
microbial gut community lives in relative balance in healthy individuals. Dysbiosis refers
to an imbalance in microbial species, which is commonly associated with impaired gut
barrier function and inflammatory activity [164]. It encompasses major traits such as loss
of beneficial microbes, expansion of pathobionts, and loss of diversity [3] (Figure 1). The
following sections will describe the key alterations found in the gut of IBD patients.
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3.2.1. Defining the Gut Microbiome in IBD
Although the gastrointestinal tract contains trillions of resident micr organisms that
include bacteria, archaea, fungi and viruses, the studies revised herein highlighted that
current research on microbiome is mainly focused on bacteria.
Bacterial Dysbiosis
It has consistently been shown that there is a disease-dependent restriction of biodiver-
sity and an imbalanced bacterial composition associated with IBD. The abundance of benefi-
cial microorganisms such as Clostridium groups IV and XIVa, Bacteroides, Suterella, Roseburia,
Bifidobacterium species and Faecalibacterium prausnitzii is reduced, whereas some pathogens
such as Proteobacteria members (including invasive and adherent Escherichia coli), Veil-
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lonellaceae, Pasteurellaceae, Fusobacterium species, and Ruminococcus gnavus are increased [4].
Most of the studies have revealed that in IBD patients, commensal bacteria are depleted and
the microbial community is less diverse [14,22,37,48,80,94,106,108,126,143,150,152,153].
The increase in the phylum Proteobacteria, which includes multiple genera considered
potentially pathogenic such as Escherichia, Salmonella, Yersinia, Desulfovibrio, Helicobacter or
Vibrio, has been extensively reported in IBD patients [17,22,34,35,58,76,113,116,126,135,165].
In the Firmicutes phylum, F. prausnitzii, an anti-inflammatory commensal bacterium,
is frequently decreased in CD, while less evidence has been reported in UC, where it is
sometimes increased and in other studies decreased [14,22,51,59,73,89,109,140,142,166,167].
Specific decrease in Roseburia spp. in patients with IBD has also been consistently
noted [56,59,76,99,115,116,130]. Both bacteria are known to be involved in the production
of butyrate, an important energy source for intestinal epithelial cells, which strengthens
gut barrier function and exerts important immunomodulatory functions [168]. In this same
phylum, the mucin degrader R. gnavus is frequently increased in IBD patients’ gut, which
may impair barrier stability and contribute to inflammation [38,76,103,111,116,132,140,144].
Fungal Dysbiosis
Despite the large body of literature on the IBD gut bacterial microbiome, little has been
published on the gut mycobiome; specifically, only nine studies reviewed herein included
fungal analysis.
Fungi are ubiquitous and their presence in the gastrointestinal tract has been demon-
strated [169]. It was already evidenced many years ago that antibodies directed against
mannoproteins of Saccharomyces cerevisiae (ASCA) were associated with CD, suggesting an
inappropriate immune response to fungi in these patients [170].
Although fungi only constitute approximately 0.1% of the total microbial community
in the gut [171], changes in gut mycobiota have been reported in IBD patients. However,
results on fungal diversity are controversial; compared to controls, some studies have
shown that fungal diversity is decreased in UC patients [107,112], and in CD, diversity
and richness have been reported to be either increased [24,63], reduced [103,133], or un-
changed [101]. Findings across fungal studies have consistently shown an increase in
fungal load, especially in Candida albicans [24,63,101,102,107,133].
Nowadays, the exact mechanisms of intestinal fungi in IBD remain unclear and
microbiome studies need to include fungi to properly address the complex challenges of
this promising field.
Viral Dysbiosis
The human gut virome includes a diverse collection of viruses, mostly bacteriophages,
directly impacting on human health [172]. In this systematic review, only seven studies
included viral analysis [87,90,93,95,129,132,136]. Alterations in IBD gut virome showed
an expansion of Caudovirales and an inverse correlation between the virome and bacterial
microbiome, suggesting an hypothesis where changes in the gut virome may affect bacterial
dysbiosis [90,95,129,136]. The use of data on both bacteriome and virome composition
would contribute to improve classification between health and disease.
These findings suggest that the loss of virus-bacterium relationships can cause micro-
biota dysbiosis and intestinal inflammation. However, whether viruses have a direct role
in IBD pathogenesis, or merely reflect underlying dysbiosis remains to be determined.
Archaeal Dysbiosis
The human gut microbiota also contains prokaryotes of the domain Archaea. Methane-
producing archaea (methanogens) have been associated with disorders of the gastroin-
testinal tract and dysbiosis. Methanogens play an important role in digestion, improving
polysaccharide fermentation by preventing accumulation of acids, reaction end-products
and hydrogen gas [173].
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The two reviewed studies including archaeal analysis have shown that the variable
prevalence of methanogens in different individuals may play an important role on IBD
pathogenesis [61,71]. Lecours et al. showed that the abundance of Methanosphaera stast-
manae in fecal samples was significantly higher in IBD patients than in healthy subjects.
Interestingly, only IBD patients developed a significant anti-Msp. stadtmanae immunoglob-
ulin G response, indicating that the composition of archaeal microbiome appears to be an
important determinant of the presence or absence of autoimmunity [61].
The other study demonstrated an inverse association between Methanobrevibacter
smithii load and susceptibility to IBD, which could be extended to IBD patients in remission
as they found that Mbb. smithii load was markedly higher in healthy subjects compared to
IBD patients [71].
Although archaeal diversity in the gastrointestinal tract is far lower than that of bacte-
ria, these microorganisms can also exert inflammatory effects and their consideration in mi-
crobiome studies may be crucial for developing optimal diagnostics and prognostics tools.
Disease Activity and Severity
Different disease activity and severity have been described among IBD patients with
a given clinically defined condition, suggesting that, in the context of microbiome dys-
function, each condition may present different microbial profiles. The reviewed studies
showed a clear difference in the gut microbiota associated with different disease activity
and severity in IBD patients.
Dysbiosis was evidenced by Tong et al. [83] at remission, where highly preserved
microbial groups accurately classified IBD status during disease quiescence, suggesting
that microbial dysbiosis in IBD may be an underlying disorder not only associated with
active disease. In general, compared to inactive disease, bacterial diversity and richness
are reduced in active disease. Studies of intestinal microbiota in active/inactive IBD
patients have consistently shown an increase in F. prausnitzii and Clostridiales in inactive
IBD compared to active IBD, and the increase in Proteobacteria in active IBD compared
to inactive IBD. Besides, F. prausnitzii and R. hominis display an inverse correlation with
disease activity [51,54,56,59,60,68,114,135,137,139,149].
Some studies showed that the genus Bifidobacterium is significantly decreased in stool
samples during the active phase of CD and UC compared to the remission
phase [43,49,68]. On the contrary, biopsies showed a higher abundance of Bifidobacterium
during active UC, and the proportion of Bifidobacterium was significantly higher in biop-
sies than in the fecal samples in active CD patients [60]. Some controversial results were
also found as other researchers did not find a correlation between microbiota and disease
actitivity [35,45,50,101,105,138].
Regarding IBD severity, different microbial abundance was detected in both biopsies
and fecal samples from patients with more aggressive disease, and gut dysbiosis was not
only related to current activity but also to the course of the disease. In biopsies, Firmicutes
showed a significant decrease and Proteobacteria a significant increase in more aggressive
CD [135], and Bifidobacterium was inversely correlated with IBD severity [54,135,149]. The
risk of flare was associated with reduced microbial richness, increased dysbiosis index and
higher individualized microbial instability [74,122,132,137,146,153].
This area is still in its infancy and some results are inconsistent between studies.
Several studies have evidenced microbiota signatures of disease activity and severity
and the likelihood of a flare-up. However, more research is necessary to identify specific
microbial taxa.
3.3. Gut Microbiome-Based Biomarkers in IBD
Ideal biomarkers should be easy to obtain, easy to determine, non-invasive, cheap, and
capable of providing rapid and reproducible results. Non-invasive tests for IBD are already
available, including serum antibodies [174,175], imaging-based screenings [176], and fecal
biomarkers [177]. However, endoscopy remains the gold standard for IBD diagnosis, as
Microorganisms 2021, 9, 977 33 of 43
the aforementioned non-invasive tests are limited to active disease and their outcome can
be interfered by diseases other than IBD limiting their clinical utility.
As a non-invasive, cost-effective technique, microbiome-based biomarkers might have
great potential for early-stage disease detection and disease course prognosis as well as for
treatment based on patient stratification. To this end, several attempts have been made to
develop indices of dysbiosis based on relative abundances of selected microbial taxa in IBD
patients compared to those of a healthy population. In stool samples, a machine learning
algorithm using a combination of 50 operational taxonomic units was able to differentiate
remission from active CD [178], and the genera Collinsella and Methanobrevibacter could be
used to differentiate between UC and CD [109]. In biopsies, Faecalibacteria and Papillibacter
were indicators of IBD status [98], F. prausnitzii and E. coli were used for differential
diagnosis of CD (ileal/colonic) [30], supervised learning classification models were able to
classify IBD at specific intestinal locations [65], and microbiome shifts predicted patient
outcome [62,64,132,137,145,154]. In biopsies, stool and blood a dysbiosis score accurately
stratified IBD patients [132].
In the previous sections, differential results on the gut microbiome between CD and
UC, IBD and healthy subjects or between different disease activities have been described.
Such research on the IBD microbiome has evidenced that (1) alterations in the abundance of
certain microbial taxa or (2) in the structure of the microbial community, (3) the decreased
bacterial richness and/or diversity and (4) the decreased microbial community stability
could be used as potential biomarkers in the field.
Nevertheless, due to the high microbiome diversity between individuals, and within
the same individual over time, the predictive value of these potential indicators is currently
far below the level required for utility in diagnosis, prognosis, or response to treatment.
Nonetheless, the increasing number of microbiome studies along with the use of longitudi-
nal approaches pave the way to the refinement of microbiome-based biomarkers as useful
disease indicators.
4. Concluding Remarks and Future Perspectives
The study of the human microbiome and its involvement in human health is nowadays
one of the most active research topics in biomedicine. A simple search for “Microbiota”
and “disease” within PubMed Database reveals almost 28,000 hits to date (august 2020).
Given the potential clinical application of the microbiome, the number of studies in this
field is rapidly increasing. However, some limitations can be found across these studies,
including different methodologic approaches, small cohort sizes, different microbiome
analysis methods and sample types and sites, main focus on bacteria, and influence of
disease activity and treatment interventions. Therefore, these limitations result in variable
findings, difficulty to establish comparison between studies and lack of reproducibility of
microbiome signatures across studies.
Recent studies based on novel DNA sequencing methods have revealed major dif-
ferences in microbial taxonomic and functional composition between IBD patients and
healthy individuals. The current knowledge guides us to move our focus from community
composition to the understanding of the interactions between microbial functions and the
IBD gut microbiome.
The microbiota is very specific to an individual and variable in time, and therefore
studies need to go from searching for correlation to searching for causation through
longitudinal approaches. One important factor that we must keep in mind when studying
the microbiome is that it is a “living entity” subject to variability. This variability is
even more evident in the IBD microbiome. To better understand the IBD–microbiome
connection, we require prospective longitudinal studies, along with following populations
with early-onset IBD. The question of whether dysbiosis precedes the development of IBD
and sets the inflammatory process, or merely reflects the altered immune and metabolic
environment of the inflamed mucosa, remains to be answered. For this reason, it is of
paramount importance to study newly diagnosed treatment-naïve patients, where the
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microbiome can be studied at the beginning of the disease and without the influence of
any IBD treatment. Developing unified approaches to the accurate quantitative assessment
of the gut microbiome would contribute to comparisons among studies and to its further
clinical application.
The main feature in IBD gut dysbiosis is the decrease in beneficial bacteria and the
increase in pathogens. Gut microbiome studies are mainly focused on bacteria, yet beyond
bacteria, the gut microbiome is composed of other microorganisms such as viruses, fungi
or archaea, which play a role in IBD etiology and/or in bacterial population control. In
addition, it is currently known that disease activity and severity influence the gut micro-
biome, thereby affecting the results. IBD can be considered as a “multimicrobial” disease
with no single causative microorganism, in which more severe disease is linked to reduced
gut microbial diversity, and proliferation or reduction in specific taxa. Therefore, future
studies should include the whole community for a deeper understanding of this disease.
The usefulness of the gut microbiome as a tool towards targeted non-invasive biomark-
ers for IBD has been evaluated by compelling studies. An acceptable biomarker may help
in early diagnosis and classification of IBD as well as in the prediction of disease outcome.
Overall, IBD clinical management would benefit from the identification of microbiome-
based biomarkers, which could provide less invasive assessment tools, enable personalized
treatments, and reduce the health care economic burden associated with IBD. Collectively,
these microbiome data represent a valuable data source that can be continually mined to
identify associations between the microbiome and IBD for a deeper pathophysiological un-
derstanding which may promote the development of clinical strategies, including disease
prevention, treatment, stratification and assessment of high-risk population.
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Table A1. PRISMA Checklist.
Section/Topic # Checklist Item Reported on Page #
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT
Structured summary 2
Provide a structured summary including, as applicable: background; objectives; data
sources; study eligibility criteria, participants, and interventions; study appraisal and
synthesis methods; results; limitations; conclusions and implications of key findings;
systematic review registration number.
1
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known. 1–2




Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address),
and, if available, provide registration information including registration number. 2
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Table A2. PRISMA Checklist.
Section/Topic # Checklist Item Reported on Page #
TITLE
Eligibility criteria 6
Specify study characteristics (e.g., PICOS, length of follow-up) and report
characteristics (e.g., years considered, language, publication status) used as criteria for
eligibility, giving rationale.
2
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact withstudy authors to identify additional studies) in the search and date last searched. 2
Search 8 Present full electronic search strategy for at least one database, including any limitsused, such that it could be repeated. 2
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematicreview, and, if applicable, included in the meta-analysis). 2
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, induplicate) and any processes for obtaining and confirming data from investigators. 2
Section/topic # Checklist item Reported on page #
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources)and any assumptions and simplifications made. N/A
Risk of bias in
individual studies 12
Describe methods used for assessing risk of bias of individual studies (including
specification of whether this was done at the study or outcome level), and how this
information is to be used in any data synthesis.
N/A
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). N/A
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done,including measures of consistency (e.g., I2) for each meta-analysis. N/A
Risk of bias across
studies 15
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g.,
publication bias, selective reporting within studies). N/A
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses,meta-regression), if done, indicating which were pre-specified. N/A
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review,with reasons for exclusions at each stage, ideally with a flow diagram. 2
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size,PICOS, follow-up period) and provide the citations. 3–8
Risk of bias within
studies 19
Present data on risk of bias of each study and, if available, any outcome level
assessment (see item 12). N/A
Results of individual
studies 20
For all outcomes considered (benefits or harms), present, for each study: (a) simple
summary data for each intervention group (b) effect estimates and confidence
intervals, ideally with a forest plot.
N/A
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals andmeasures of consistency. N/A
Risk of bias across
studies 22 Present results of any assessment of risk of bias across studies (see Item 15). N/A
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses,meta-regression [see Item 16]). N/A
Section/topic # Checklist item Reported on page #
DISCUSSION
Summary of evidence 24
Summarize the main findings including the strength of evidence for each main
outcome; consider their relevance to key groups (e.g., healthcare providers, users, and
policy makers).
N/A
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level(e.g., incomplete retrieval of identified research, reporting bias). N/A
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, andimplications for future research. 8–9
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supplyof data); role of funders for the systematic review. 9
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